TRACERx MRD Results Showcase ppmSeq’s Ultra-Sensitive ctDNA Detection at AACR

At the recent AACR meeting, Ultima Genomics unveiled compelling findings regarding its ppmSeq technology, which demonstrates ultra-sensitive detection of circulating tumor DNA (ctDNA) relevant to minimal residual disease (MRD). This technology is pivotal for assessing treatment efficacy and predicting relapse in cancer patients, a critical need in oncology.

The TRACERx study, one of the largest tumor evolution projects funded by Cancer Research UK, provides a robust framework for this research. It encompasses multi-region and multi-time-point genetic data from over 3,200 tumor samples, enabling a comprehensive analysis of cancer evolution and treatment resistance. The initial MRD data presented by Charles Swanton, FRCP, BSc, PhD, indicates that ppmSeq can achieve high analytical sensitivity for ctDNA detection at low single-digit parts-per-million.

Swanton emphasized the importance of enhancing ctDNA detection sensitivity for broader MRD monitoring applications. The findings, including those from Labcorp’s independent studies, highlight ppmSeq’s ability to accurately distinguish between cancerous and non-cancerous samples, thereby minimizing false positives. This advancement suggests that whole genome MRD monitoring could become a practical and scalable solution in clinical settings, potentially transforming cancer management strategies.